Natco Pharma Appoints Amit Parekh as CFO, S.V.V.N. Appa Rao Retires
Natco Pharma's CFO, Mr. S.V.V.N. Appa Rao, will retire on February 12, 2026. Mr. Amit Parekh is appointed as the new CFO from February 13, 2026. Mr. Kalakuntla Srinivas Rao also joins as EVP - Pharma Division from February 12, 2026.
Changes in key management positions like CFO can have a medium-term impact on company strategy and financial operations.
The announcement details routine management changes, including a retirement and appointments, which are standard corporate events and do not inherently signal positive or negative performance.
Natco Pharma Limited announced key changes in its senior management following a Board of Directors meeting held on February 12, 2026.
Mr. S.V.V.N. Appa Rao, the Chief Financial Officer, will superannuate effective from the closure of business hours on February 12, 2026. Concurrently, the Board approved the appointment of Mr. Amit Parekh, currently the Executive Vice President – Finance and Accounts, as the new Chief Financial Officer of the Company, effective February 13, 2026.
In addition to the CFO transition, Mr. Kalakuntla Srinivas Rao has been appointed as the Executive Vice President – Pharma Division, also effective February 12, 2026. Mr. Parekh brings over 23 years of experience in financial management across various industries, including prior roles at Dr. Reddy's Laboratories. Mr. Rao has more than 25 years of experience in the pharmaceutical sector, with expertise in operations and regulatory compliance.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under key management changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.